Citations

Showing 10 of 108162 citations.

Clinical Features, Prognostic Factors, and Treatment Interventions for Ulceration in Patients With Infantile Hemangioma
Shah, Sonal D. , Witman, Patricia M., Harfmann, Katya , Bradley, Flora , Blei, Francine , Alsumait, Anwar, Gupta, Deepti , Covelli, Isabela, Streicher, Jenna L., Cotton, Colleen , Tollefson, Megha M. , Nguyen, Henry, Hunt, Raegan , Frieden, Ilona J. , Tollefson, Megha, Faith, Esteban Fernández , Pope, Elena , Moore‐Clingenpeel, Melissa

Mayo Clinic

JAMA Dermatology | March 31, 2021 | Volume: 157 | Issue: 5 | Pages: 566

10.1001/jamadermatol.2021.0469 | PMID 33787840 Get It

Therapy-Induced Senescence: Opportunities to Improve Anticancer Therapy
Prasanna, Pataje G.S. , Citrin, Deborah E. , Hildesheim, Jeffrey, Ahmed, Mansoor M. , Venkatachalam, Sundar, Riscuta, Gabriela , Xi, Dan , Zheng, Guangrong , Deursen, Jan van, Goronzy, Jörg J. , Kron, Stephen J. , Campisi, Judith , Brown, Stephen L. , Niedernhofer, Laura J. , Gius, David , Schmitt, Clemens A. , Abazeed, Mohamed E. , Kirkland, James L. , Lowe, Scott W. , Mendonca, Marc S. , Burma, Sandeep , Zhou, Daohong , Coleman, C. Norman , Prasanna, Pataje G , Goronzy, Jorg , Sharpless, Norman E , Campisi, Judith , Georgakilas, Alexandros G , Paris, Francois , Gewirtz, David A , Schmitt, Clemens A , Abazeed, Mohamed E , Kirkland, James L , Richmond, Ann , Romesser, Paul B , Gil, Jesus , Mendonca, Marc S , Niedernhofer, Laura J , Anscher, Mitchell S. , O’Loghlen, Ana , Georgakilas, Alexandros G. , Romesser, Paul B.

Mayo Clinic

JNCI: Journal of the National Cancer Institute | March 31, 2021 | Volume: 113 | Issue: 10 | Pages: 1285-1298

10.1093/jnci/djab064 | PMID 33792717 Get It

Abstract Cellular senescence is an essential tumor suppressive mechanism that prevents the propagation of oncogenically activated, genetically unstable, and/or damaged cells. Induction of tumor cell senescence is also one of the underlying mechanisms by which cancer therapies exert antitumor activity. However, an increasing body of evidence from preclinical studies demonstrates that radiation and chemotherapy cause accumulation of senescent cells (SnCs) both in tumor and normal tissue. SnCs in tumors can, paradoxically, promote tumor relapse, metastasis, and resistance to therapy, in part, through expression of the senescence-associated secretory phenotype. In addition, SnCs in normal tissue can contribute to certain radiation- and chemotherapy-induced side effects. Because of its multiple roles, cellular senescence could serve as an important target in the fight against cancer. This commentary provides a summary of the discussion at the National Cancer Institute Workshop on Radiation, Senescence, and Cancer (August 10-11, 2020, National Cancer Institute, Bethesda, MD) regarding the current status of senescence research, heterogeneity of therapy-induced senescence, current status of senotherapeutics and molecular biomarkers, a concept of “one-two punch” cancer therapy (consisting of therapeutics to induce tumor cell senescence followed by selective clearance of SnCs), and its integration with personalized adaptive tumor therapy. It also identifies key knowledge gaps and outlines future directions in this emerging field to improve treatment outcomes for cancer patients.
Extracorporeal Life Support Organization (ELSO): Guidelines for Pediatric Cardiac Failure
Brown, Georgia , Moynihan, Katie M. , Deatrick, Kristopher B., Sandhu, Hitesh , Aganga, Devon O. , Menon, Anuradha P. , Rozen, Thomas, Raman, Lakshmi , Alexander, Peta , Peek, Giles J. , Sandhu, Hitesh S , Aganga, Devon , Hoskote, Aparna U. , Deshpande, Shriprasad R.

Mayo Clinic

ASAIO Journal | March 31, 2021 | Volume: 67 | Issue: 5 | Pages: 463-475

10.1097/mat.0000000000001431 | PMID 33788796 Get It

These guidelines are applicable to neonates and children with cardiac failure as indication for extracorporeal life support. These guidelines address patient selection, management during extracorporeal membrane oxygenation, and pathways for weaning support or bridging to other therapies. Equally important issues, such as personnel, training, credentialing, resources, follow-up, reporting, and quality assurance, are addressed in other Extracorporeal Life Support Organization documents or are center-specific.
Multiple Instability Events at Initial Presentation Are the Major Predictor of Failure of Nonoperative Treatment for Anterior Shoulder Instability
Duethman, Nicholas C., Bernard, Christopher D. , Leland, Devin P. , Wilbur, Ryan R. , Krych, Aaron J. , Dahm, Diane L., Leland, Devin, Barlow, Jonathan D. , Krych, Aaron J , Camp, Christopher L.

Mayo Clinic

Arthroscopy | March 31, 2021 | Volume: 37 | Issue: 8 | Pages: 2432-2439

10.1016/j.arthro.2021.03.047 | PMID 33812027 Get It

Purpose To define the success rate of initial nonoperative treatment for traumatic anterior shoulder instability in a defined U.S. geographic population, describe factors that predict conversion to surgery after initial nonoperative management, and describe the long‐term outcomes of nonoperative treatment after the index traumatic anterior instability event. Methods The Rochester Epidemiology Project database was used to identify patients aged 14 to 39 years treated for anterior shoulder instability between 1994 and 2016. Patient demographic characteristics, comorbidities, injury characteristics, and imaging were evaluated. Patients treated nonoperatively for the first 6 months after the index instability event were analyzed to determine long‐term outcomes (recurrence rate, pain at last follow‐up, radiographic outcomes), the success rate of continued nonoperative treatment (no conversion to surgery), and factors associated with conversion to surgery (patient and injury characteristics). Survivorship free of surgery was reported with a Kaplan‐Meier survival curve, and Cox proportional hazards models were used to evaluate association of variables with conversion to surgery. Results A total of 379 patients met the study criteria, with an average follow‐up period of 10.2 years (range, 0.53‐25.00 years). The average age was 23.9 years, the mean body mass index was 26.2, and 100% of instability events were due to trauma. Of the shoulders, 79 (20.1%) ultimately failed initial nonoperative treatment and progressed to surgery. At final follow‐up, the rate of recurrent instability was 52.3% in the group treated definitively without surgery, and the recurrence rate decreased from 92.4% to 10.1% in patients who underwent conversion to surgical treatment. Factors associated with conversion to surgery included 2 or more subluxations prior to the first evaluation (hazard ratio [HR], 1.82; P = .002), 2 or more dislocations prior to the first evaluation (HR, 1.76; P = .006), and recurrent instability at follow‐up (HR, 4.21; P < .001). Conclusions Most patients younger than 40 years with shoulder instability who were initially treated nonoperatively for 6 months were definitively treated without surgery. Ultimately, 35% of these patients experienced recurrent dislocations after 6 months of conservative treatment and 20% underwent surgical treatment. In most patients who underwent conversion to surgical treatment, surgery was performed within 12.5 years of their first instability event. Patients who experienced multiple instability events before or after consultation were more likely to undergo conversion to surgery after initial nonoperative management. Level of Evidence Level III, retrospective database review.
The Exosome‐Associated Tetraspanin CD63 Contributes to the Efficient Assembly and Infectivity of the Hepatitis B Virus
Ninomiya, Masashi , Inoue, Jun , Krueger, Eugene W. , Cao, Hong , McNiven, Mark A. , Chen, Jing , Masamune, Atsushi

Mayo Clinic

Hepatology Communications | March 31, 2021 | Volume: 5 | Issue: 7 | Pages: 1238-1251

10.1002/hep4.1709 | PMID 34278172 Get It

Currently, the hepatocellular trafficking pathways that are used by the hepatitis B virus (HBV) during viral infection and shedding are poorly defined. It is known that the HBV uses late endosomal and multivesicular body (MVB) compartments for assembly and release. The intraluminal vesicles (ILVs) generated within MVBs have also been implicated in the late synthesis stages of a variety of pathogenic viruses. We recently observed that the HBV within infected hepatocytes appears to associate with the tetraspanin protein CD63, known to be a prominent and essential component of ILVs. Immunofluorescence microscopy of HBV‐expressing cells showed that CD63 colocalized with HBV proteins (large hepatitis B surface antigens [LHBs] and hepatitis B core) and labeled an exceptionally large number of secreted extracellular vesicles of uniform size. Small interfering RNA (siRNA)–mediated depletion of CD63 induced a substantial accumulation of intracellular LHBs protein but did not alter the levels of either intracellular or extracellular HBV DNA, nor pregenomic RNA. Consistent with these findings, we found that markedly less LHBs protein was associated with the released HBV particles from CD63 siRNA‐treated cells. Importantly, the HBV viral particles that were shed from CD63‐depleted cells were substantially less infective than those collected from control cells with normal CD63 levels. Conclusion: These findings implicate the tetraspanin protein CD63 as a marker and an important component in the formation and release of infectious HBV particles.
Report of National Brain Tumor Society roundtable workshop on innovating brain tumor clinical trials: building on lessons learned from COVID-19 experience
Lee, Eudocia Q. , Selig, Wendy , Meehan, Clair, Bacha, Jeffrey , Barone, Amy , Chang, Susan M. , Galanis, Evanthia , Hassan, Islam , Kalidas, Chitkala , Lassman, Andrew B. , Sahebjam, Solmaz , Welch, Mary , Yung, W.K. Alfred, Zadeh, Gelareh , Arons, David, Wen, Patrick Y. , Galanis, Evanthia , Khasraw, Mustafa , Zadeh, Gelareh , Bloomquist, Erik W. , Chang, Susan Marina , Groot, John de , Khasraw, Mustafa , Kvedar, Joseph C. , Puduvalli, Vinay K. , Schwamm, Lee H. , Tamir, Sharon, Wen, Patrick Yung

Mayo Clinic

Neuro-Oncology | March 31, 2021 | Volume: 23 | Issue: 8 | Pages: 1252-1260

10.1093/neuonc/noab082 | PMID 33822177 Get It

Abstract On July 24, 2020, a workshop sponsored by the National Brain Tumor Society was held on innovating brain tumor clinical trials based on lessons learned from the COVID-19 experience. Various stakeholders from the brain tumor community participated including the US Food and Drug Administration (FDA), academic and community clinicians, researchers, industry, clinical research organizations, patients and patient advocates, and representatives from the Society for Neuro-Oncology and the National Cancer Institute. This report summarizes the workshop and proposes ways to incorporate lessons learned from COVID-19 to brain tumor clinical trials including the increased use of telemedicine and decentralized trial models as opportunities for practical innovation with potential long-term impact on clinical trial design and implementation.
Stem Cell Therapy for Microvascular Injury Associated with Ischemic Nephropathy
Textor, Stephen C., Abumoawad, Abdu, Saad, Ahmed , Ferguson, Christopher M. , Dietz, Allan B. , Ferguson, Christopher, Dietz, Allan, Dietz, Allan B

Mayo Clinic

Cells | March 31, 2021 | Volume: 10 | Issue: 4 | Pages: 765

10.3390/cells10040765 | PMID 33807289 Get It

Ischemic nephropathy reflects progressive loss of kidney function due to large vessel atherosclerotic occlusive disease. Recent studies indicate that this process is characterized by microvascular rarefaction, increased tissue hypoxia and activation of inflammatory processes of tissue injury. This review summarizes the rationale and application of functional MR imaging to evaluate tissue oxygenation in human subjects that defines the limits of renal adaptation to reduction in blood flow, development of increasingly severe tissue hypoxia and recruitment of inflammatory injury pathways in ischemic nephropathy. Human mesenchymal stromal/stem cells (MSC) are capable of modifying angiogenic pathways and immune responses, but the potency of these effects vary between individuals and various clinical characteristics including age and chronic kidney disease and levels of hypoxia. We summarize recently completed first-in-human studies applying intrarenal infusion of autologous adipose-derived MSC in human subjects with ischemic nephropathy that demonstrate a rise in blood flow and reduction in tissue hypoxia consistent with partial repair of microvascular injury, even without restoring main renal arterial blood flow. Inflammatory biomarkers in the renal vein of post-stenotic kidneys fell after MSC infusion. These changes were associated with modest but significant dose-related increments in kidney function. These data provide support a role for autologous MSC in repair of microvascular injury associated with tissue hypoxia.
Mesenchymal Stem/Stromal Cell-Derived Extracellular Vesicles Elicit Better Preservation of the Intra-Renal Microvasculature Than Renal Revascularization in Pigs with Renovascular Disease
Ferguson, Christopher M. , Farahani, Rahele A., Zhu, Xiang-Yang, Jordan, Kyra L., Saadiq, Ishran M. , Lerman, Lilach O. , Eirin, Alfonso , Lerman, Lilach O , Eirin, Alfonso , Tang, Hui Jun , Lerman, Amir

Mayo Clinic

Cells | March 31, 2021 | Volume: 10 | Issue: 4 | Pages: 763

10.3390/cells10040763 | PMID 33807246 Get It

Background: Percutaneous transluminal renal angioplasty (PTRA) confers clinical and mortality benefits in select ‘high-risk’ patients with renovascular disease (RVD). Intra-renal-delivered extracellular vesicles (EVs) released from mesenchymal stem/stromal cells (MSCs) protect the kidney in experimental RVD, but have not been compared side-by-side to clinically applied interventions, such as PTRA. We hypothesized that MSC-derived EVs can comparably protect the post-stenotic kidney via direct tissue effects. Methods: Five groups of pigs (n = 6 each) were studied after 16 weeks of RVD, RVD treated 4 weeks earlier with either PTRA or MSC-derived EVs, and normal controls. Single-kidney renal blood flow (RBF) and glomerular filtration rate (GFR) were assessed in vivo with multi-detector CT, and renal microvascular architecture (3D micro CT) and injury pathways ex vivo. Results: Despite sustained hypertension, EVs conferred greater improvement of intra-renal microvascular and peritubular capillary density compared to PTRA, associated with attenuation of renal inflammation, oxidative stress, and tubulo-interstitial fibrosis. Nevertheless, stenotic kidney RBF and GFR similarly rose in both PTRA- and EV-treated pigs compared RVD + Sham. mRNA sequencing reveled that EVs were enriched with pro-angiogenic, anti-inflammatory, and antioxidants genes. Conclusion: MSC-derived EVs elicit a better preservation of the stenotic kidney microvasculature and greater attenuation of renal injury and fibrosis compared to PTRA, possibly partly attributed to their cargo of vasculo-protective genes. Yet, both strategies similarly improve renal hemodynamics and function. These observations shed light on diverse mechanisms implicated in improvement of post-stenotic kidney function and position EVs as a promising therapeutic intervention in RVD.
Examining career shadowing in genetic counseling: Perspectives of shadowees, program directors, and genetic counselors
Agre, Katherine , Essendrup, Anna, Koellner, Christine M., Rust, Laura, Deyle, David R. , Koellner, Christine, Deyle, David

Mayo Clinic

Journal of Genetic Counseling | March 31, 2021 | Volume: 30 | Issue: 5 | Pages: 1428-1439

10.1002/jgc4.1411 | PMID 33788324 Get It

Abstract Career shadowing can be a valuable opportunity for individuals to experience the daily activities of a working professional. However, there is no published research regarding the impact of shadowing for individuals hoping to pursue a career as a genetic counselor (GC) (termed ‘shadowees’). Additionally, little is known about the impact of shadowing on practicing GCs, nor the value of shadowing in the application and admission process for genetic counseling graduate programs. For this study, three independent surveys were developed and sent to three stakeholder groups: shadowees in the Minnesota Genetic Counseling Experience Program, program directors within the Association of Genetic Counseling Program Directors, and members of the National Society of Genetic Counselors. Quantitative and qualitative analyses were performed on responses. The survey of shadowees ( n = 55) found that the majority believed that shadowing had either a ‘very’ or ‘somewhat positive’ impact on their decision to become a GC and on their application to a genetic counseling graduate program (81.8% and 91.3%, respectively). Of the participating program director respondents ( n = 43), the majority indicated that having shadowing experience was either ‘moderately’ or ‘extremely important’ in offering an interview or for acceptance into a graduate program (63% and 56%, respectively). While programs differ in evaluation of shadowing experiences, most program directors indicated that an applicant's ability to speak to their shadowing experience was the most important factor in admissions consideration (71%). Among the GCs surveyed ( n = 325), 69.2% have hosted shadowees; of these, 82.7% indicated that hosting a shadowee decreases their efficiency at work. Despite this drawback, the majority of respondents expressed a willingness and motivation to host shadowees to help the shadowee (64.8%) and to promote the genetic counseling profession (32.6%). These findings suggest the need for additional research and the development of resources for GCs to increase access of career shadowing.
The Addition of C‐Reactive Protein and von Willebrand Factor to Model for End‐Stage Liver Disease‐Sodium Improves Prediction of Waitlist Mortality
Starlinger, Patrick , Ahn, Joseph , Gyöeri, Georg , Pereyra, David , Alva‐Ruiz, Roberto, Hackl, Hubert , Reiberger, Thomas , Trauner, Michael , Santol, Jonas , Simbrunner, Benedikt , Mandorfer, Mattias , Kamath, Patrick S. , Mullan, Aidan, Gyoeri, Georg P , Pereyra, David , Alva-Ruiz, Roberto, Reiberger, Thomas , Mandorfer, Mattias , Ahn, Joseph C , Starlinger, Patrick , Hackl, Hubert , Santol, Jonas , Mullan, Aidan F. , Györi, Georg, Berlakovich, Gabriela , Heimbach, Julie K.

Mayo Clinic

Hepatology | March 31, 2021 | Volume: 74 | Issue: 3 | Pages: 1533-1545

10.1002/hep.31838 | PMID 33786862 Get It

Background and Aims Patients with cirrhosis on the liver transplant (LT) waiting list may die or be removed because of complications of portal hypertension (PH) or infections. von Willebrand factor antigen (vWF‐Ag) and C‐reactive protein (CRP) are simple, broadly available markers of these processes. Approach and Results We determined whether addition of vWF‐Ag and CRP to the Model for End‐Stage Liver Disease‐Sodium (MELD‐Na) score improves risk stratification of patients awaiting LT. CRP and vWF‐Ag at LT listing were assessed in two independent cohorts (Medical University of Vienna [exploration cohort] and Mayo Clinic Rochester [validation cohort]). Clinical characteristics, MELD‐Na, and mortality on the waiting list were recorded. Prediction of 3‐month waiting list mortality was assessed by receiver operating characteristics curve (ROC‐AUC). In order to explore potential mechanisms underlying the prognostic utility of vWF‐Ag and CRP in this setting, we evaluated their association with PH, bacterial translocation, systemic inflammation, and circulatory dysfunction. In the exploration cohort (n = 269) vWF‐Ag and CRP both improved the predictive value of MELD‐Na for 3‐month waitlist mortality and showed the highest predictive value when combined (AUC: MELD‐Na, 0.764; MELD‐Na + CRP, 0.790; MELD‐Na + vWF, 0.803; MELD‐Na + CRP + vWF‐Ag, 0.824). Results were confirmed in an independent validation cohort (n = 129; AUC: MELD‐Na, 0.677; MELD‐Na + CRP + vWF‐Ag, 0.882). vWF‐Ag was independently associated with PH and inflammatory biomarkers, whereas CRP closely, and MELD independently, correlated with biomarkers of bacterial translocation/inflammation. Conclusions The addition of vWF‐Ag and CRP—reflecting central pathophysiological mechanisms of PH, bacterial translocation, and inflammation, that are all drivers of mortality on the waiting list for LT—to the MELD‐Na score improves prediction of waitlist mortality. Using the vWFAg‐CRP‐MELD‐Na model for prioritizing organ allocation may improve prediction of waitlist mortality and decrease waitlist mortality.